| Outcome Measures: |
Primary: Changes from baseline of antidiuretic function parameters (BNP), Blood samples for BNP (pg/mL)., Before starting SGLT2i and 30 days the starting SGLT2i therapy|Changes from baseline of antidiuretic function parameters (BNP), Blood samples for BNP (pg/mL)., 90 days after starting SGLT2i therapy|Changes from baseline of antidiuretic function parameters (vasopressin), Blood samples for Copeptin (pmol/L)., Before starting SGLT2i and 30 days the starting SGLT2i therapy|Changes from baseline of antidiuretic function parameters (vasopressin), Blood samples for Copeptin (pmol/L)., 90 days after starting SGLT2i therapy|Changes from baseline of antidiuretic function parameters (osmolality), Samples for plasma osmolality (mOsm/Kg)., Before starting SGLT2i and 30 days the starting SGLT2i therapy|Changes from baseline of antidiuretic function parameters (osmolality), Samples for urinary osmolality (mOsm/Kg)., Before starting SGLT2i and 30 days the starting SGLT2i therapy|Changes from baseline of antidiuretic function parameters (osmolality), Samples for plasma osmolality (mOsm/Kg)., 90 days after starting SGLT2i therapy|Changes from baseline of antidiuretic function parameters (osmolality), Samples for urinary osmolality (mOsm/Kg)., 90 days after starting SGLT2i therapy|Changes from baseline of antidiuretic function parameters (sodium balance), Samples for serum sodium (mmol/L)., Before starting SGLT2i and 30 days the starting SGLT2i therapy|Changes from baseline of antidiuretic function parameters (sodium balance), Samples for serum sodium (mmol/L)., 90 days after starting SGLT2i therapy|Changes from baseline of antidiuretic function parameters (sodium balance), Samples for urinary sodium (mmol/L)., Before starting SGLT2i and 30 days the starting SGLT2i therapy|Changes from baseline of antidiuretic function parameters (sodium balance), Samples for urinary sodium (mmol/L)., 90 days after starting SGLT2i therapy|Changes from baseline of antidiuretic function parameters (potassium balance), Samples for serum potassium (mmol/L)., Before starting SGLT2i and 30 days the starting SGLT2i therapy|Changes from baseline of antidiuretic function parameters (potassium balance), Samples for serum potassium (mmol/L)., 90 days after starting SGLT2i therapy|Changes from baseline of antidiuretic function parameters (potassium balance), Samples for urinary potassium (mmol/L)., Before starting SGLT2i and 30 days the starting SGLT2i therapy|Changes from baseline of antidiuretic function parameters (potassium balance), Samples for urinary potassium (mmol/L)., 90 days after starting SGLT2i therapy|Changes from baseline of renin-angiotensin-aldosterone system parameters (renin), Blood samples for plasma renin activity (ng/mL/h)., Before starting SGLT2i and 30 days the starting SGLT2i therapy|Changes from baseline of renin-angiotensin-aldosterone system parameters (renin), Blood samples for plasma renin activity (ng/mL/h)., 90 days after starting SGLT2i therapy|Long term changes from baseline of renin-angiotensin-aldosterone system parameters aldosterone), Blood samples for aldosterone (pg/mL)., Before starting SGLT2i and 30 days the starting SGLT2i therapy|Long term changes from baseline of renin-angiotensin-aldosterone system parameters, Blood samples for plasma renin activity (ng/mL/h) and aldosterone (pg/mL), 90 days after starting SGLT2i therapy | Secondary: Changes from baseline of blood pressure values (ABPM), Mean Systolic and Diastolic Blood Pressure (mmHg), Before starting SGLT2i and 90 days after the starting|Changes from baseline of body composition, Variation of parameters of Bioelectrical Impedance Analysis (BIA), Before starting SGLT2i and 90 days after the starting|Changes in basal glicemic control, Blood samples for basal glucose (mg/dL)., Before starting SGLT2i and 90 days after the starting|Changes in long term glicemic control, Blood samples for Glycated albumin (mmol/mol)., Before starting SGLT2i and 90 days after the starting
|
